Live Breaking News & Updates on Shanghai junshi biosciences co ltd

Stay informed with the latest breaking news from Shanghai junshi biosciences co ltd on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Shanghai junshi biosciences co ltd and stay connected to the pulse of your community

Junshi Biosciences Announces NDA Acceptance in Hong Kong

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...

Maryland , United-states , United-kingdom , Beijing , China , San-francisco , California , Suzhou , Jiangsu , Singapore , Malaysia , Hong-kong-special-administrative-region

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

India , Malaysia , Suzhou , Jiangsu , China , Beijing , Singapore , Jordan , Australia , Hong-kong-special-administrative-region , Hong-kong-general- , Hong-kong

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

China , Peking , Beijing , Jun-guo , National-medical-products-administration-of-china , Shanghai-junshi-biosciences-co-ltd , University-cancer-hospital , International-metastatic-renal-cell-carcinoma-database-consortium , National-medical-products-administration , Peking-university-cancer-hospital , News , Global-oncology

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Australia , Singapore , Maryland , United-states , Shanghai , China , Suzhou , Jiangsu , Peking , Beijing , Guangzhou , Guangdong

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing.com

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing.com
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

United-states , Beijing , China , Australia , Renji , Henan , Peking , Guangzhou , Guangdong , Shanghai , Singapore , San-francisco

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.

Guangzhou , Guangdong , China , United-states , San-francisco , California , Suzhou , Jiangsu , Australia , Shanghai , Maryland , Beijing

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

Ottawa , Ontario , Canada , Vietnam , Republic-of , Uruguay , Brunei , Laos , China , Shanghai , Brazil , Guangzhou

Junshi Biosciences Announces 2023 Full Year Financial

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...

Indonesia , Brunei , Panama , Beijing , China , Shanghai , New-zealand , India , Argentina , Guangzhou , Guangdong , Uruguay

Junshi Biosciences Announces 2023 Full Year Financial Results And Provides Corporate Updates

Junshi Biosciences Announces 2023 Full Year Financial Results And Provides Corporate Updates
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Argentina , New-zealand , Australia , Suzhou , Jiangsu , China , India , Beijing , Panama , San-francisco , California , United-states

Reviewing Shanghai Junshi Biosciences (OTCMKTS:SHJBF) and SAB Biotherapeutics (NASDAQ:SABS)

Shanghai Junshi Biosciences (OTCMKTS:SHJBF – Get Free Report) and SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability. Earnings & Valuation This table compares Shanghai […]

Sioux-falls , South-dakota , United-states , Shanghai , China , Junshi-biosciences , Shanghai-junshi-biosciences-co-ltd , Biotherapeutics-inc , Shanghai-junshi-biosciences , Get-free-report , Shanghai-junshi